The US Food and Drug Administration has approved the stimulant lisdexamfetamine to treat binge-eating disorder, the first product to be approved for the condition.
The US Food and Drug Administration has approved the stimulant lisdexamfetamine to treat binge-eating disorder, the first product to be approved for the condition.
The US Food and Drug Administration has approved the stimulant lisdexamfetamine to treat binge-eating disorder, the first product to be approved for the condition.
The FDA is seeking a cap on nicotine levels in cigarettes and certain tobacco products at minimally or nonaddictive levels. This initiative, if finalized, would be what the FDA calls a “significant step”...
The FDA is seeking a cap on nicotine levels in cigarettes and certain tobacco products at minimally or nonaddictive levels. This initiative, if finalized, would be what the FDA calls a “significant step”...
The FDA is seeking a cap on nicotine levels in cigarettes and certain tobacco products at minimally or nonaddictive levels. This initiative, if finalized, would be what the FDA calls a “significant step”...
The FDA is seeking a cap on nicotine levels in cigarettes and certain tobacco products at minimally or nonaddictive levels. This initiative, if finalized, would be what the FDA calls a “significant step”...
The FDA is seeking a cap on nicotine levels in cigarettes and certain tobacco products at minimally or nonaddictive levels. This initiative, if finalized, would be what the FDA calls a “significant step”...
